Quantitative assessment of 99mtc-depreotide uptake in patients with non-small-cell lung cancer: Immunohistochemical correlations

Acta Radiologica

Volumn 50, Issue 8, 2009, Pages 902-908

  Herlin, G ^a   Klbeck, K G ^a   Menzel, P L ^b   Svensson, L ^a   Aspelin, P ^a   Capitanio, A ^a   Axelsson, R ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

99mTc depreotide; Lung cancer; Prognostic factor; Radionuclide imaging; Somatostatin

Indexed keywords

BIOLOGICAL ORGANS; CELLS; COMPUTERIZED TOMOGRAPHY; CYTOLOGY; DISEASES; IMAGE SEGMENTATION; NUCLEAR MEDICINE; TUMORS;

LUNG CANCER; PROGNOSTIC FACTORS; RADIONUCLIDE IMAGING; SOMATOSTATIN; ^99MTC-DEPREOTIDE;

DIAGNOSIS;

DEPREOTIDE TC 99M; DRUG DERIVATIVE; SOMATOSTATIN; SOMATOSTATIN RECEPTOR; TECHNETIUM COMPLEX;

ADULT; AGED; ARTICLE; DIFFERENTIAL DIAGNOSIS; ENZYME IMMUNOASSAY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; SCINTISCANNING;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MALE; MIDDLE AGED; ORGANOTECHNETIUM COMPOUNDS; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN;

EID: 70350022628     PISSN: 02841851     EISSN: 16000455     Source Type: Journal    
DOI: 10.1080/02841850903127477     Document Type: Article

References (27)

1. Cheng YL, Lee SC, Harn HJ, Chen CJ, Chang YC, Chen JC, et al. Prognostic prediction of the immunohistochemical expression of p53 and p16 in the resected non small cell lung cancer. Eur J Cardiothorac Surg 2003;/23:/221-8.
2. Murakami I, Hiyama K, Ishioka S, Yamakido M, Kasagi F, Yokosaki Y. p53 gene mutations are associated with shortened survival in patients with advanced non small cell lung cancer: an analysis of medically managed patients. Clin Cancer Res 2000;/6:/526-30.
3. Shiba M, Kohno H, Kakizawa K, Iizasa T, Otsuji M, Saitoh Y, et al. Ki-67 immunostaining and other prognostic factors including tobacco smoking in patients with resected non small cell lung carcinoma. Cancer 2000;/89:/1457-65.
4. Greatens TM, Niehans GA, Rubins JB, Jessurun J, Kratzke RA, Maddaus MA, et al. Do molecular markers predict survival in non-small-cell lung cancer? Am J Respir Crit Care Med 1998;/157:/1093-7.
5. Quinlan DC, Davidson AG, Summers CL, Warden HE, Doshi HM. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 1992;/52:/4828-31.
6. Mitsudomi T, Oyama T, Kusano T, Osaki T, Nakanishi R, Shirakusa T. Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer. J Natl Cancer Inst 1993;/85:/2018-23.
7. Lee JS, Yoon A, Kalapurakal SK, Ro JY, Lee JJ, Tu N, et al. Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor. J Clin Oncol 1995;/13:/1893-903.
8. Passlick B, Izbicki JR, Hä ussinger K, Thetter O, Pantel K. Immunohistochemical detection of P53 protein is not associated with a poor prognosis in non-small-cell lung cancer. J Thorac Cardiovasc Surg 1995;/109:/1205-11.
9. Apolinario RM, van der Valk P, de Jong JS, Deville W, van Ark-Otte J, Dingemans AM, et al. Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer. J Clin Oncol 1997;/ 15:/2456-66.
10. Pence JC, Kerns BJ, Dodge RK, Iglehart JD. Prognostic signicance of the proliferation index in surgically resected non-small-cell lung cancer. Arch Surg 1993;/ 128:/1382-90.
11. Nieder C, Andratschke N, Jeremic B, Molls M. Comparison of serum growth factors and tumor markers as prognostic factors for survival in non-small cell lung cancer. Anticancer Res 2003;/23:/5117-23.
12. Patz EF Jr, Campa MJ, Gottlin EB, Kusmartseva I, Guan XR, Herndon JE 2nd. Panel of serum biomarkers for the diagnosis of lung cancer. J Clin Oncol 2007;/25:/ 5578-5583
13. Hoang JK, Hoagland LF, Coleman RE, Coan AD, Herndon JE 2nd, Patz EF Jr. Prognostic value of uorine-18 uorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma. J Clin Oncol 2008;/26:/ 1459-1464
14. Hanin FX, Lonneux M, Cornet J, Noirhomme P, Coulon C, Distexhe J, et al. Prognostic value of FDG uptake in early stage non-small cell lung cancer. Eur J Cardiothorac Surg 2008;/33:/819-23.
15. Ba? a? th M, Kö lbeck KG, Danielsson R. Somatostatin receptor scintigraphy with 99m-Tc-depreotide (NeoSpect) in discriminating between malignant and benign lesions in the diagnosis of lung cancer: a pilot study. Acta Radiol 2004;/45:/833-9.
16. Naalsund A, Maublant J, on behalf of the European NeoSpect trial group. The solitary pulmonary nodule* is it malignant or benign? Diagnostic performance of 99m-Tc-depreotide SPECT. Respiration 2006;73: 634-641
17. Danielsson R, Ba? a? th M, Svensson L, Forslö w U, Kö lbeck KG. Imaging of regional lymph node metastases with 99m-Tc-depreotide in patients with lung cancer. Eur J Nucl Med Mol Imaging 2005;/32:/925-31.
18. Kahn D, Menda Y, Kernstine K, Bushnell D, McLaughlin K, Miller S, et al. The utility of 99m Tc depreotide compared with F-18 uorodeoxyglucose positron emission tomography and surgical staging in patients with suspected non-small cell lung cancer. Chest 2004;/125:/494-501.
19. Virgolini I, Leimer M, Handmaker H, Lastoria S, Bischof C, Muto P, et al. Somatostatin receptor subtype specicity and in vivo binding of a novel tumor tracer, 99mTc-P829. Cancer Res 1998;/58:/1850-9.
20. Axelsson R, Herlin G, Ba? a? th M, Aspelin P, Kö lbeck KG. Role of scintigraphy with technetium-99m depreotide in the diagnosis and management of patients with suspected lung cancer. Acta Radiol 2008;/49:/295-302.
21. O'Byrne KJ, Carney DN. Somatostatin and the lung. Lung Cancer 1993;/10:/151-72.
22. Fujita T, Yamaji Y, Sato M, Murao K, Takahara J. Gene expression of somatostatin receptor subtypes, SSTR1 and SSTR2 in human lung cancer cell lines. Life Sci 1994;/55:/1797-806.
23. O'Byrne KJ, Halmos G, Pinski J, Groot K, Szepeshazi K, Schally AV, et al. Somatostatin receptor expression in lung cancer. Eur J Cancer 1994;/30:/1682-7.
24. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. WHO classication of tumors: pathology and genetics of tumors of the lung, pleura, thymus and heart. Lyon: IARC Press; 2004.
25. Kwekkeboom DJ, Kho GS, Lamberts SW, Reubi JC, Laissue JA, Krenning EP. The value of octreotide scintigraphy in patients with lung cancer. Eur J Nucl Med 1994;/21:/1106-13.
26. Machac J, Krynyckyi B, Kim C. Peptide and antibody imaging in lung cancer. Semin Nucl Med 2002;/32:/ 276-292
27. Shih WJ, Samayoa L. Tc-99m depreotide detecting malignant pulmonary nodules: histopathologic correlation with semi-quantitative tumor-to-normal lung ratio. Clin Nucl Med 2004;/29:/171-6.